Risultati per: Valutazione delle co-morbidità nei pazienti con psoriasi

I dati del progetto Pascnet coordinato dalla Cattolica di Milano

Objectives
This study aims to estimate the impact of the co-occurrence of behavioural risk factors on mortality in the Spanish adult population.

Design
Population-based cohort study based on data from the 2011–2012 Spanish National Health Survey and the 2014 European Health Survey (n=35 053 participants ≥15 years of age) both linked to mortality data as of December 2022. Risk factors included tobacco use, high-risk alcohol consumption, low adherence to the Mediterranean diet, leisure time sedentary lifestyle and body mass index outside the 18.5–24.9 kg/m2 range. Deaths from any cause (n=2784), from diseases of the circulatory system (n=678) and from tumours (n=869) were identified. Standardised rate differences (SRD) and standardised rate ratios (SRR) were estimated using Poisson regression models adjusted for sociodemographic variables.

Results
Compared with those with no unhealthy behaviours, overall mortality risk increased gradually as the co-occurrence of risk behaviours increased. Individuals with two factors had an SRD of 3.0 deaths per 1000 person-years (95% CI 1.8; 4.3) and an SRR of 1.88 (95% CI 1.35; 2.62). A coexistence of five risk factors increased SRD and SRR to 11.5 (95% CI 7.2; 15.8) and 4.34 (95% CI 2.84; 6.63), respectively. The association was stronger among individuals under 65 years of age, whereas it did not vary by sex and educational level. Those reporting five risk factors had SRRs of 6.35 (95% CI 2.91; 13.83) and 2.57 (95% CI 1.11; 5.98) for tumour-related and cardiovascular disease mortality, respectively.

Conclusions
The co-occurrence of unhealthy behaviours increases the risk of overall and cause-specific mortality. Targeting multiple risk behaviours should be incorporated into the public health strategy.

IncontraDonna, grazie al teatro benefici mentali e relazionali

Studio del Policlinico Federico II

L’impianto di un nuovo stent evita l’intervento a cuore aperto

Potranno effettuare in un’unica giornata tutti gli esami

Oncologi, la preservazione della fertilità tra le nuove problematiche

Attese dei letti rallentano accessi:12 minuti in più per ogni malato

Introduction
Breaking the chain of transmission of an infectious disease pathogen is a major public health priority. The challenges of understanding, describing and predicting the transmission dynamics of infections have led to a wide range of mathematical, statistical and biological research problems. Advances in diagnostic laboratory procedures with the ability to test multiple pathogens simultaneously mean that co-infections are increasingly being detected, yet little is known about the impact of co-infections in shaping the course of an infection, infectivity, and pathogen replication rate. This is particularly true of the apparent synergistic effects of viral and bacterial co-infections, which present the greatest threats to public health because of their lethal nature and complex dynamics. This systematic review protocol is the foundation of a critical review of co-infection modelling and an assessment of the key features of the models.

Methods and analysis
MEDLINE through PubMed, Web of Science, medRxiv and Scopus will be systematically searched between 1 December 2024 and 31 January 2025 for studies published between January 1980 and December 2024. Three reviewers will screen articles independently for eligibility, and quality assessment will be performed using the TRACE (TRAnsparent and Comprehensive Ecological) standard modelling guide. Data will be extracted using an Excel template in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis standard reporting guidelines. This systematic review will apply the SWiM (Synthesis Without Meta-analysis) approach in its narrative synthesis coupled with tables and figures to present data. The synthesis will highlight key dynamical co-infection model features such as assumptions, data fitting and estimation methods, validation and sensitivity analyses, optimal control analyses, and the impact of co-infections.

Ethics and dissemination
Ethics approval is not required for a systematic review since it will be based on published work. The output of this study will be submitted for publication in a peer-reviewed journal.

PROSPERO registration number
CRD42023481247.

Introduction
Fear of recurrence is a transdiagnostic problem experienced by people with psychosis, which is associated with anxiety, depression and risk of future relapse events. Despite this, there is a lack of available psychological interventions for fear of recurrence, and psychological therapies for schizophrenia are often poorly implemented in general. However, low-intensity psychological therapy is available for people who experience fear of recurrence in the context of cancer, which means there is an opportunity to learn what has worked in a well-implemented psychological therapy to see if any learning can be adapted for schizophrenia care. This article describes the design, methods and expected data collection of development, acceptability, feasibility, and preliminary outcome signals for a coproduced low-intensity psychological intervention targeting fear of relapse in people with schizophrenia (INDIGO), which aims to develop an acceptable psychological intervention for fear of recurrence.

Methods and analysis
INDIGO will use a mixed-methods approach to co-design and deliver a model and treatment pathway for a psychological intervention for people diagnosed with schizophrenia who experience fear of recurrence. The study will consist of four stages. First, in-depth interviews with mental health staff and people diagnosed with schizophrenia (with a further social network mapping task for patient participants only) to develop the intervention. Second, in-depth interviews with people who have accessed the Glasgow Fear of Recurrence service and oncology staff will be conducted to inform further development of the intervention. Third, co-design workshops will be held with people diagnosed with schizophrenia and mental health staff to co-design intervention content and the treatment pathway. Finally, people diagnosed with schizophrenia will be presented with an intervention prototype and invited to complete ‘think-aloud’ interviews to gather further feedback so adaptations can be implemented.

Ethics and dissemination
The INDIGO study received ethical approval from East Midlands—Nottingham 2 Research Ethics Committee (24/EM/0124). The study received independent peer review prior to funding. This co-design study is expected to lead to a future feasibility study and, if indicated, a randomised controlled trial.

Ricoverato il 60%, il 13,5 in terapia intensiva, mortalità 10,6%

Questore e suoi collaboratori all’ospedale pediatrico di Trieste

Positivo a influenza 28% dei test; presenti Covid e rhinovirus

La malattia interessa 1 milione e mezzo di persone in Italia

Objective
The objective of this study is to review the current literature on the health co-benefits of emission reduction strategies and the methods and tools available to assess them.

Design
Systematic review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Data sources
PubMed, Scopus, Web of Science, ScienceDirect and GreenFILE were searched from January of 2017 to March of 2023.

Eligibility criteria
We included original, peer-reviewed journal articles that described emission (ambient air pollutant and greenhouse gases) reduction strategies and assessed their health co-benefits.

Data extraction and synthesis
Two independent reviewers employed standardised methods to search, screen and code the included studies, documenting their findings in an Excel spreadsheet.

Results
From 6687 articles, 82 were included. Most studies show that emissions reduction strategies improve air quality, reducing mortality and morbidity. Health risk assessment and health impact assessment are common, though procedures may cause confusion. About 33% used established models like the integrated exposure-response and global exposure mortality model. Out of all studies, 16% of them used Environmental Benefits Mapping and Analysis Program—Community Edition. Only 17.8% carried out cost–benefit analyses, but these show economic worth in investing in emission reduction strategies.

Conclusions
Emission reduction strategies significantly enhance human health, with potential co-benefits offsetting intervention costs, which can be an incentive for action in low and middle-income countries. This review emphasises investing in cost–benefit analyses and research, particularly in regions with limited studies on emission reduction and health co-benefits. It provides decision-makers insights into selecting assessment methods and underscores the ongoing need for model and tool evaluation.

PROSPERO registration number
CRD42022332480.